BR0110841A - Suspensões aquosas estabilizadas para uso parenteral - Google Patents

Suspensões aquosas estabilizadas para uso parenteral

Info

Publication number
BR0110841A
BR0110841A BR0110841-7A BR0110841A BR0110841A BR 0110841 A BR0110841 A BR 0110841A BR 0110841 A BR0110841 A BR 0110841A BR 0110841 A BR0110841 A BR 0110841A
Authority
BR
Brazil
Prior art keywords
aqueous suspensions
parenteral use
stabilized aqueous
stabilized
biologically active
Prior art date
Application number
BR0110841-7A
Other languages
English (en)
Inventor
Giuseppe Colombo
Alessandro Martini
Lloyd E Fox
Original Assignee
Pharmacia Italia Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Upjohn Co filed Critical Pharmacia Italia Spa
Publication of BR0110841A publication Critical patent/BR0110841A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"SUSPENSõES AQUOSAS ESTABILIZADAS PARA USO PARENTERAL". Uma formulação de suspensão aquosa farmacêutica para administração parenteral tendo pH substancialmente estabilizado, compreendendo um composto biologicamente ativo e uma concentração de L-Metionina, eficaz para controle de pH. Preferivelmente, o composto biologicamente ativo é um composto esteroidal, por exemplo exemestano, acetato de medroxiprogesterona e cipionato de estradiol ou uma combinação de acetato de medroxiprogesterona e cipionato de estradiol.
BR0110841-7A 2000-05-15 2001-04-25 Suspensões aquosas estabilizadas para uso parenteral BR0110841A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use
PCT/EP2001/004643 WO2001087266A1 (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use

Publications (1)

Publication Number Publication Date
BR0110841A true BR0110841A (pt) 2003-03-11

Family

ID=24283530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110841-7A BR0110841A (pt) 2000-05-15 2001-04-25 Suspensões aquosas estabilizadas para uso parenteral

Country Status (30)

Country Link
US (3) US6495534B2 (pt)
EP (1) EP1282402B1 (pt)
JP (1) JP4205341B2 (pt)
KR (1) KR100828957B1 (pt)
CN (1) CN100473376C (pt)
AR (3) AR029924A1 (pt)
AT (1) ATE313316T1 (pt)
AU (2) AU2001267371B2 (pt)
BR (1) BR0110841A (pt)
CA (1) CA2409059C (pt)
CZ (1) CZ303872B6 (pt)
DE (1) DE60116084T2 (pt)
DK (1) DK1282402T3 (pt)
EA (1) EA007682B1 (pt)
EE (1) EE05376B1 (pt)
ES (1) ES2254443T3 (pt)
HK (1) HK1054194B (pt)
HU (1) HU229800B1 (pt)
IL (2) IL152537A (pt)
IN (1) IN224279B (pt)
MX (1) MXPA02011195A (pt)
NO (1) NO332215B1 (pt)
NZ (1) NZ522324A (pt)
PE (1) PE20011322A1 (pt)
PL (1) PL203075B1 (pt)
SI (1) SI1282402T1 (pt)
SK (1) SK287641B6 (pt)
TW (1) TWI256310B (pt)
WO (1) WO2001087266A1 (pt)
ZA (1) ZA200208738B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
US7387623B2 (en) 2002-08-21 2008-06-17 Pfizer Inc. Injectable pharmaceutical suspension in a two-chamber vial
AU2003290647A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
JP2006522133A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 非水性単一相の媒体、及び、そのような媒体を利用するフォーミュレーション
SI1660009T1 (sl) * 2003-09-03 2015-07-31 Miscon Trading S.A. Metode za zdravljenje endometrioze
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
WO2006031720A2 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
WO2007095341A2 (en) * 2006-02-15 2007-08-23 Tika Läkemedel Ab Sterilization of corticosteroids with reduced mass loss
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
JP5624766B2 (ja) * 2006-09-27 2014-11-12 イーグル・ファーマシューティカルズ・インコーポレーテッド アルコールを含まないアルガトロバン製剤
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
WO2009026473A2 (en) * 2007-08-21 2009-02-26 Hollis-Eden Pharmaceuticals, Inc. Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
EP3150702B1 (en) 2011-06-19 2021-05-19 DNA Genotek, Inc. Devices, solutions and methods for sample collection
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2924335A1 (en) 2013-09-17 2015-03-26 Terapio Corporation Methods of preventing or treating mucositis using rlip76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US9265396B1 (en) 2015-03-16 2016-02-23 Irobot Corporation Autonomous floor cleaning with removable pad
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017149492A1 (en) * 2016-03-02 2017-09-08 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
US20190134059A1 (en) * 2016-05-06 2019-05-09 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
WO2019048906A1 (en) * 2017-09-07 2019-03-14 Teva Pharmaceutical Industries Ltd. INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE
MX2020002606A (es) * 2017-09-07 2020-10-05 Teva Pharma Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso.
EP3706719A1 (en) * 2017-11-08 2020-09-16 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP7482777B2 (ja) * 2018-01-11 2024-05-14 バイロファーマ バイオロジクス エルエルシー 安定なコルチコステロイド組成物
BR112021004194A2 (pt) * 2018-09-07 2021-05-25 Teva Pharmaceutical Industries Ltd composições injetáveis de acetato de medroxiprogesterona e métodos de uso
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
AU2019384801A1 (en) 2018-11-20 2021-06-10 Spectrum Solutions, Llc Sample collection system including sealing cap and valve
IT201900002857A1 (it) 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022245939A1 (en) * 2021-05-19 2022-11-24 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
ATE99943T1 (de) 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
JP2001501619A (ja) 1996-10-04 2001-02-06 アムジェン インコーポレーテッド ｍｐｌリガンドを含有する医薬組成物
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US6923956B1 (en) * 1997-09-23 2005-08-02 Rentschler Biotechnologie Gmbh Liquid interferon-β formulations
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
DE69913116T2 (de) 1998-04-02 2004-06-03 Akzo Nobel N.V. Orale flüssige lösung enthaltend das antidepressivum mirtazapine
HU227347B1 (en) 1999-10-04 2011-04-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Also Published As

Publication number Publication date
SK15982002A3 (sk) 2003-05-02
EE200200631A (et) 2004-04-15
DE60116084T2 (de) 2006-08-17
IN224279B (pt) 2005-02-25
EP1282402B1 (en) 2005-12-21
CN100473376C (zh) 2009-04-01
SK287641B6 (sk) 2011-05-06
CA2409059C (en) 2006-04-18
AR029924A1 (es) 2003-07-23
KR100828957B1 (ko) 2008-05-13
US20020115645A1 (en) 2002-08-22
PE20011322A1 (es) 2002-01-10
CA2409059A1 (en) 2001-11-22
US20030114430A1 (en) 2003-06-19
AU6737101A (en) 2001-11-26
HK1054194B (zh) 2010-02-12
AR111695A2 (es) 2019-08-07
HK1054194A1 (en) 2003-11-21
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
ES2254443T3 (es) 2006-06-16
JP4205341B2 (ja) 2009-01-07
ZA200208738B (en) 2003-10-29
WO2001087266A1 (en) 2001-11-22
DK1282402T3 (da) 2006-05-08
NO20025431L (no) 2003-01-13
EA007682B1 (ru) 2006-12-29
IL165888A0 (en) 2006-01-15
EP1282402A1 (en) 2003-02-12
JP2003533467A (ja) 2003-11-11
HUP0302021A2 (hu) 2003-09-29
AU2001267371B2 (en) 2006-01-05
US6495534B2 (en) 2002-12-17
HUP0302021A3 (en) 2011-03-28
IL152537A (en) 2007-06-17
ATE313316T1 (de) 2006-01-15
CZ303872B6 (cs) 2013-06-05
AR098830A2 (es) 2016-06-15
CN1429101A (zh) 2003-07-09
PL365793A1 (en) 2005-01-10
NZ522324A (en) 2005-02-25
EE05376B1 (et) 2011-02-15
EA200201208A1 (ru) 2003-04-24
HU229800B1 (en) 2014-07-28
IL152537A0 (en) 2003-05-29
US20030130245A1 (en) 2003-07-10
NO332215B1 (no) 2012-07-30
NO20025431D0 (no) 2002-11-13
MXPA02011195A (es) 2003-03-10
PL203075B1 (pl) 2009-08-31
SI1282402T1 (sl) 2006-04-30
TWI256310B (en) 2006-06-11
KR20030020280A (ko) 2003-03-08

Similar Documents

Publication Publication Date Title
BR0110841A (pt) Suspensões aquosas estabilizadas para uso parenteral
HUP0000979A1 (hu) FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények
ATE301675T1 (de) Methode zur lösung, reinigung und rückfaltung von protein
BR0112101A (pt) Interleucina 2 estabilizada
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
BR9911031A (pt) Novas formulações em partìculas
BR0214254A (pt) Pó filmogênio micronizado e composição farmacêutica, cosmética ou neutracêutica
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
UA92146C2 (ru) Стабилизированная жидкая композиция, которая содержит интерферон
BR9909357A (pt) Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina
MY114828A (en) High spf perpiration-resistant sunscreen
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
BR9913457A (pt) Neuroproteção
BR9913515A (pt) Análogo de grf hidrófobo, formulação farmacêutica, uso de análogo de grf, e, processo para o diagnóstico de deficiências de hormÈnio de crescimento em pacientes
SE9800729D0 (sv) New topical formulation I
BRPI0417585A (pt) composição pregabalina
IT1254627B (it) Formulazioni di steroidi
WO2001087262A3 (en) Stabilized steroidal suspension
PT1171100E (pt) Composicao farmaceutica solubilizada para administracao parenteral
TR199900730T2 (xx) S�v� alendronat form�lasyonlar�
AU7285498A (en) Urea and thiourea derivatives of glycopeptides
EP1232740A3 (en) Hair-growing agent
BR9903179A (pt) Uso de uma combinação de uma proteìna osteoindutiva e um fator de dorsalização para indução de cartilagem
BR9810558A (pt) Composição quìmica agrìcola em suspensão aquosa
NO983650L (no) Krystallinske progestagener

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: O EXAME TECNICO NOTIFICADO NA RPI 2028, DE 17/11/2009, APRESENTOU DESPACHO DE CODIGO 7.1, INDICANDO CIENCIA DE PARECER. ATRAVES DA PETICAO NO 020100012974, DE 12/02/2010, A REQUERENTE APRESENTOU SUA RESPOSTA ACERCA DO PARECER NOTIFICADO NA RPI 2028, DE 17/11/2009. NO ENTANTO, A PETICAO SUPRACITADA AFETUOU PAGEMENTO RELATIVO A " CUMPRIMENTO DE EXIGENCIA TECNICA" ( CUJO DESPACHO E 6.1 ) EM QUE VALOR A SER PAGO E MENOR DO QUE O DEVIDO EM CASOS DE CIENCIA DE PARECEER. DESSE MODO, A FIM DE DAR CONTINUIDADE AO EXAME DO PEDIDO, A REQUERENTE DEVERA COMPLEMENTAR A RETRIBUICAO EQUIVALENTE AO DESPACHO NOTIFICADO NA RPI 2028, DE 17/11/2009.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 25 DA LPI

B15Z Prolongation of time limit refused

Free format text: NEGADA A SOLICITACAO DE DEVOLUCAO DE PRAZO UMA VEZ QUE A MESMA NAO FOI APRESENTADA AO INPI NA VIGENCIA DO PRAZO PREVISTO PARA A PRATICA DO ATO, CONFORME DEFINIDO NO ART. 221 DA LPI E NO ART. 2O, PARAGRAFO UNICO, DA RESOLUCAO NO 116/04. A COPIA DO PARECER (DAS RAZOES) PODERA SER SOLICITADA ATRAVES DO FORMULARIO 1.05. (DESTA DATA CORRE O PRAZO DE 60 (SESSENTA) DIAS PARA EVENTUAL RECURSO DO INTERESSADO).

B12F Other appeals [chapter 12.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: PHARMACIA ITALIA S.P.A. (IT) , PHARMACIA AND UPJOH

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20130006126/RJ DE 23/01/2013, E NECESSARIO APRESENTAR DOCUMENTO QUE COMPROVE O QUE FOI SOLICITADO NA PETICAO.

B25A Requested transfer of rights approved

Owner name: PHARMACIA AND UPJOHN COMPANY (US) , PHARMACIA ITAL

B25D Requested change of name of applicant approved

Owner name: PHARMACIA ITALIA S.R.L (IT) , PHARMACIA AND UPJOHN

B12F Other appeals [chapter 12.6 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15W Others matters related to applications: legal action concerning application

Free format text: INPI-52400.061317/15 ORIGEM: JUIZO DA 025A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0119264-17.2015.4.02.5101 ACAO ORDINARIA PARA CONCESSAO DA PATENTE PROVENIENTE DO PEDIDO DE PATENTE AUTOR: PFIZER ITALIA S.R.L. E PHARMACIA AND UPJOHN COMPANY LLC REU: AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI.

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: PFIZER ITALIA S.R.L (IT) , PHARMACIA AND UPJOHN CO

Free format text: RETIFICACAO DO DESPACHO (25.1) TRANSFERENCIA DEFERIDA PUBLICADO NA RPI NO 2274, DE 05/08/2014, QUANTO AO ITEM (71) NOME DO DEPOSITANTE . ONDE SE LE: PHARMACIA ITALIA S.R.L (IT) , PHARMACIA AND UPJOHN COMPANY LLC (US) LEIA-SE: PFIZER ITALIA S.R.L (IT) , PHARMACIA AND UPJOHN COMPANY LLC (US)

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: A PETICAO DE NO 860140023832, APRESENTADA EM 27/02/2014, EM VIRTUDE DO DISPOSTO NOS ARTS. 219, II, DA LPI (LEI 9279 / 96) DE 14/05/1996, E CONSIDERADA COMO PETICAO NAO CONHECIDA UMA VEZ QUE A TRANSFERENCIA SOLICITADA FORA DEFERIDA NA RPI 2274, DE 05/08/2014, E RETIFICADA NA RPI 2344, DE 08/12/2015.

B15N Others concerning applications: notification of judicial decision

Free format text: INPI NO 52400.061317/2015-06 25A VARA FEDERAL DO RIO DE JANEIRO PROCEDIMENTO COMUM NO 0119264-17.2015.4.02.5101/RJ AUTOR: PHARMACIA AND UP JOHN COMPANY LLC AUTOR: PFIZER ITALIA S.R.L. REU: INPI-INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL DECISAO: INTIME-SE O INPI NOS TERMOS DO ART. 497, DO CPC, PARA QUE NO PRAZO DE 15 (QUINZE) DIAS, PROVIDENCIE A ANOTACAO E PUBLICACAO DA DECISAO TRANSITADA EM JULGADO NA REVISTA DA PROPRIEDADE INDUSTRIAL, PARA CIENCIA DE TERCEIROS, NA FORMA PREVISTA DO ART. 175, 2O, DA LEI NO 9.279/96.